4.4 Article

ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression

期刊

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
卷 97, 期 1, 页码 47-55

出版社

FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2011.049270

关键词

ATM; chronic lymphocytic leukemia; gene expression profiling; MLPA; del11q

资金

  1. Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan
  2. Ministero dell'Universita e Ricerca (MIUR), Rome
  3. Compagnia di San Paolo, Turin
  4. Ministero della Salute, Rome
  5. Fondazione Cenci Bolognetti, Rome, Italy

向作者/读者索取更多资源

Background The genetic characterization of chronic lymphocytic leukemia cells correlates with the behavior, progression and response to treatment of the disease. Design and Methods Our aim was to investigate the role of ATM gene alterations, their biological consequences and their value in predicting disease progression. The ATM gene was analyzed by denaturing high performance liquid chromatography and multiplex ligation probe amplification in a series of patients at diagnosis. The results were correlated with immunoglobulin gene mutations, cytogenetic abnormalities, ZAP-70 and CD38 expression, TP53 mutations, gene expression profile and treatment-free interval. Results Mutational screening of the ATM gene identified point mutations in 8/57 cases (14%). Multiplex ligation probe amplification analysis identified six patients with 11q deletion: all of them had at least 20% of deleted cells, analyzed by fluorescent in situ hybridization. Overall, ATM point mutations and deletions were detected in 14/57 (24.6%) cases at presentation, representing the most common unfavorable genetic anomalies in chronic lymphocytic leukemia, also in stage A patients. Patients with deleted or mutated ATM had a significantly shorter treatment-free interval compared to patients without ATM alterations. ATM-mutated cases had a peculiar gene expression profile characterized by the deregulation of genes involved in apoptosis and DNA repair. Finally, definition of the structure of the ATM-mutated protein led to a hypothesis that functional abnormalities are responsible for the unfavorable clinical course of patients carrying these point mutations. Conclusions ATM alterations are present at diagnosis in about 25% of individuals with chronic lymphocytic leukemia; these alterations are associated with a peculiar gene expression pattern and a shorter treatment-free interval.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study

Francesca Romana Mauro, Francesca Paoloni, Stefano Molica, Gianluigi Reda, Livio Trentin, Paolo Sportoletti, Monia Marchetti, Daniela Pietrasanta, Roberto Marasca, Gianluca Gaidano, Marta Coscia, Caterina Stelitano, Donato Mannina, Nicola Di Renzo, Fiorella Ilariucci, Anna Marina Liberati, Lorella Orsucci, Francesca Re, Monica Tani, Gerardo Musuraca, Daniela Gottardi, Pier Luigi Zinzani, Alessandro Gozzetti, Annalia Molinari, Massimo Gentile, Annalisa Chiarenza, Luca Laurenti, Marzia Varettoni, Adalberto Ibatici, Roberta Murru, Valeria Ruocco, Ilaria Del Giudice, Maria Stefania De Propris, Irene Della Starza, Sara Raponi, Mauro Nanni, Paola Fazi, Antonino Neri, Anna Guarini, Gian Matteo Rigolin, Alfonso Piciocchi, Antonio Cuneo, Robin Foa

Summary: The efficacy, safety, and discontinuation rates of the ibrutinib and rituximab regimen were investigated in previously untreated and unfit patients with chronic lymphocytic leukemia (CLL). The combination treatment showed sustained disease control in over half of the unfit patients, but careful monitoring is required to prevent and manage adverse events.

CANCERS (2022)

Article Oncology

A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial

Gian Maria Zaccaria, Simone Ferrero, Eva Hoster, Roberto Passera, Andrea Evangelista, Elisa Genuardi, Daniela Drandi, Marco Ghislieri, Daniela Barbero, Ilaria Del Giudice, Monica Tani, Riccardo Moia, Stefano Volpetti, Maria Giuseppina Cabras, Nicola Di Renzo, Francesco Merli, Daniele Vallisa, Michele Spina, Anna Pascarella, Giancarlo Latte, Caterina Patti, Alberto Fabbri, Attilio Guarini, Umberto Vitolo, Olivier Hermine, Hanneke C. Kluin-Nelemans, Sergio Cortelazzo, Martin Dreyling, Marco Ladetto

Summary: In this study, machine learning techniques were applied to analyze clinical data of patients with MCL and to build a prognostic model for evaluating survival rate. This is the first application of machine learning in a prospective clinical trial on MCL lymphoma, and the developed model is expected to play a significant role in risk stratification.

CANCERS (2022)

Letter Hematology

Hairy cell leukaemia with low CD103 expression: A rare but important diagnostic pitfall

Maria Stefania De Propris, Paolo Musiu, Stefania Intoppa, Maria Grazia Nardacci, Alessandra Pucciarini, Alessia Santi, Nadia Peragine, Martina Canichella, Maria Lucia De Luca, Gianna Maria D'Elia, Ilaria Del Giudice, Alessandro Pulsoni, Brunangelo Falini, Anna Guarini, Maurizio Martelli, Enrico Tiacci, Robin Foa

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Letter Oncology

Early CD49d downmodulation in chronic lymphocytic leukemia patients treated front-line with ibrutinib plus rituximab predicts long-term response

Nadia Peragine, Maria Stefania De Propris, Stefania Intoppa, Maria Laura Milani, Francesca Romana Mauro, Antonio Cuneo, Gian Matteo Rigolin, Ilaria Del Giudice, Robin Foa, Anna Guarini

LEUKEMIA & LYMPHOMA (2022)

Article Oncology

Circulating cell-free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre-analytical biases

Roberta Soscia, Irene Della Starza, Lucia Anna De Novi, Caterina Ilari, Michela Ansuinelli, Marzia Cavalli, Vittorio Bellomarino, Luciana Cafforio, Mariangela Di Trani, Giovanni Cazzaniga, Grazia Fazio, Alessandra Santoro, Domenico Salemi, Orietta Spinelli, Manuela Tosi, Carolina Terragna, Valentina Robustelli, Teresa Bellissimo, Gioia Colafigli, Massimo Breccia, Sabina Chiaretti, Alice Di Rocco, Maurizio Martelli, Anna Guarini, Ilaria Del Giudice, Robin Foa

Summary: Circulating tumor DNA (ctDNA) has become the most studied molecule in blood. Analysis of plasma samples from patients with different diseases revealed variations in ctDNA release, limiting its use for minimal residual disease monitoring. However, an amplification system proved effective in increasing ctDNA amounts and can be used for diagnosis and follow-up samples.

HEMATOLOGICAL ONCOLOGY (2023)

Letter Oncology

Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia

Riccardo Moia, Riccardo Dondolin, Maria Stefania De Propris, Donatella Talotta, Samir Mouhssine, Francesca Perutelli, Gianluigi Reda, Veronica Mattiello, Gian Matteo Rigolin, Marina Motta, Jacopo Olivieri, Renato Fanin, Omar Perbellini, Isacco Ferrarini, Francesca Romana Mauro, Ilaria Del Giudice, Luca Laurenti, Annamaria Tomasso, Massimo Gentile, Anna Maria Frustaci, Alessandra Tedeschi, Alessandro Gozzetti, Caterina Stelitano, Carlo Visco, Carol Moreno, Francesco Forconi, Roberto Marasca, Marta Coscia, Davide Rossi, Robin Foa, Gianluca Gaidano

HEMATOLOGICAL ONCOLOGY (2023)

Letter Hematology

Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter Real-World study

Shai Levi, Yotam Bronstein, Neta Goldschmidt, Fortunato Morabito, Tomer Ziv-Baran, Giovanni Del Poeta, Osnat Bairey, Maria Ilaria Del Principe, Riva Fineman, Francesca Romana Mauro, Odit Gutwein, Gianluigi Reda, Rosa Ruchlemer, Paolo Sportoletti, Luca Laurenti, Lev Shvidel, Marta Coscia, Tamar Tadmor, Marzia Varettoni, Ariel Aviv, Roberta Murru, Andrei Braester, Annalisa Chiarenza, Andrea Visentin, Daniela Pietrasanta, Giacomo Loseto, Antonella Zucchetto, Riccardo Bomben, Jacopo Olivieri, Antonio Neri, Davide Rossi, Gianluca Gaidano, Livio Trentin, Robin Foa, Antonio Cuneo, Chava Perry, Valter Gattei, Massimo Gentile, Yair Herishanu

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Meeting Abstract Hematology

Impact of Anti-Sars-Cov-2 Monoclonal Antibodies in the Management of Patients with Lymphoma and COVID19: A Retrospective Study

Giovanni Manfredi Assanto, Alice Di Rocco, Francesco Malfona, Marcello Capriata, Ilaria Del Giudice, Luigi Petrucci, Paola Girardi, Gianna Maria D'elia, Maurizio Martelli, Giuseppe Gentile, Alessandra Micozzi, Alessandro Pulsoni

Article Oncology

Impact of anti-SARS-CoV-2 monoclonal antibodies in the management of patients with lymphoma and COVID19: A retrospective study

Giovanni Manfredi Assanto, Alice Di Rocco, Francesco Malfona, Marcello Capriata, Ilaria Del Giudice, Luigi Petrucci, Paola Girardi, Gianna Maria D'Elia, Maurizio Martelli, Giuseppe Gentile, Alessandra Micozzi, Alessandro Pulsoni

Summary: COVID-19 in lymphoma patients has a high mortality rate, but treatment with anti-SARS-CoV-2 monoclonal antibodies can decrease mortality, reduce complications, and decrease the need for oxygen support. The use of anti-COVID antibodies in vaccinated patients may improve survival rates. Active hematological disease, exposure to bendamustine, and comorbidities are independent factors predicting death.

HEMATOLOGICAL ONCOLOGY (2023)

Letter Hematology

The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia

Fortunato Morabito, Giovanni Tripepi, Francesca Romana Mauro, Luca Laurenti, Gianluigi Reda, Riccardo Moia, Adalgisa Condoluci, Iolanda Vincelli, Annalisa Chiarenza, Ernesto Vigna, Enrica Antonia Martino, Antonella Bruzzese, Sabrina Mezzatesta, Roberta Laureana, Giovanna Cutrona, Francesco Di Raimondo, Gilberto Fronza, Antonella Zucchetto, Riccardo Bomben, Francesca Maria Rossi, Jacopo Olivieri, Francesco Zaja, Davide Rossi, Gianluca Gaidano, Maria Ilaria Del Principe, Fiorella Ilariucci, Giovanni Del Poeta, Manlio Ferrarini, Antonino Neri, Valter Gattei, Massimo Gentile

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Letter Hematology

Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature

Ilaria Del Giudice, Luca Vincenzo Cappelli, Julio Delgado, Carsten Utoft Niemann, Michael Asger Andersen, Emelie Hamotal Curovic Rotbain, Kathrine Aarup, Renata Walewska, Andrea Visentin, Marina Deodato, Anna Maria Frustaci, Chiara Cavalloni, Massimo Gentile, Mohamed A. Yassin, Deepesh Lad, Lydia Scarfo, Max Flogegard, Mattias Mattsson, Sara Raponi, Caterina Ilari, Irene Della Starza, Ester M. Orlandi, Alessandra Tedeschi, Livio Trentin, Gianpietro Semenzato, Anna Guarini, Paolo Ghia, Emili Montserrat, Robin Foa

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Letter Hematology

Pre-exposure prophylaxis with tixagevimab/cilgavimab in patients with chronic lymphocytic leukaemia treated with targeted agents

Francesca R. Mauro, Andrea Visentin, Diana Giannarelli, Maria C. Molinari, Giulia Proietti, Marco Petrella, Francesco Angotzi, Sara Pepe, Livio Trentin, Silvia Baroncelli, Emanuela Giombini, Silvia Meschi, Fabrizio Maggi, Daniele Focosi

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Article Oncology

Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study

Francesca R. Mauro, Diana Giannarelli, Clementina M. Galluzzo, Andrea Visentin, Anna M. Frustaci, Paolo Sportoletti, Candida Vitale, Gianluigi Reda, Massimo Gentile, Luciano Levato, Roberta Murru, Daniele Armiento, Maria C. Molinari, Giulia Proietti, Sara Pepe, Filomena De Falco, Veronica Mattiello, Luca Barabino, Roberta Amici, Marta Coscia, Alessandra Tedeschi, Corrado Girmenia, Livio Trentin, Silvia Baroncelli

Summary: This study investigated the COVID-19 morbidity in 200 chronic lymphocytic leukemia (CLL) patients after receiving the SARS-CoV-2 vaccine. The results showed that 41% of patients contracted COVID-19, with 26% requiring hospitalization and 4% dying. Age, prior treatment, and TP53 gene mutation were significantly associated with vaccine response and susceptibility. The study highlights the importance of prevention and mitigation of COVID-19 in CLL patients.

CANCERS (2023)

Article Hematology

Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi

Manuel Gotti, Roberta Sciarra, Alessandro Pulsoni, Francesco Merli, Stefano Luminari, Caterina Zerbi, Livio Trentin, Alessandro Re, Chiara Rusconi, Simonetta Viviani, Andrea Rossi, Federica Cocito, Barbara Botto, Erika Meli, Antonello Pinto, Irene Dogliotti, Guido Gini, Benedetta Puccini, Francesca Ricci, Luca Nassi, Alberto Fabbri, Anna Marina Liberati, Michele Merli, Andrea Riccardo Filippi, Maurizio Bonfichi, Valentina Zoboli, Germana Tartaglia, Giorgia Annechini, Gianna Maria D'Elia, Ilaria Del Giudice, Isabel Alvarez, Andrea Visentin, Stefano Pravato, Daniela Dalceggio, Chiara Pagani, Silvia Ferrari, Caterina Cristinelli, Tanja Lazic, Virginia Valeria Ferretti, Umberto Ricardi, Luca Arcaini

Summary: In this study, baseline characteristics of 308 consecutive NLPHL patients diagnosed in 19 Italian centers from 2000 to 2018 were retrospectively analyzed. With a median follow-up of 8.4 years for treated patients, the estimated 5-year overall survival was 97.8% and 5-year progression-free survival was 84.5%. After adjusting for various factors, patients with stage II or more showed superior progression-free survival with immunochemotherapy compared to chemotherapy alone.

HEMASPHERE (2023)

Letter Hematology

Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study

Andrea Visentin, Francesca Romana Mauro, Lydia Scarfo, Massimo Gentile, Lucia Farina, Gianluigi Reda, Isacco Ferrarini, Giulia Proietti, Enrico Derenzini, Francesca Cibien, Candida Vitale, Alessandro Sanna, Daniela Pietrasanta, Monia Marchetti, Roberta Murru, Gian Matteo Rigolin, Paolo Sportoletti, Valentina Trimarco, Chiara Adele Cavarretta, Francesco Angotzi, Alessandro Cellini, Valeria Ruocco, Ivan Zatta, Luca Laurenti, Stefano Molica, Marta Coscia, Paolo Ghia, Robin Foa, Antonio Cuneo, Livio Trentin

AMERICAN JOURNAL OF HEMATOLOGY (2023)

暂无数据